Pharma-Bio Serv, Inc. Files 8-K on Corporate Governance Changes
Ticker: PBSV · Form: 8-K · Filed: May 2, 2024 · CIK: 1304161
| Field | Detail |
|---|---|
| Company | Pharma-Bio Serv, Inc. (PBSV) |
| Form Type | 8-K |
| Filed Date | May 2, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, management-change, filing
Related Tickers: PBSV
TL;DR
Pharma-Bio Serv (PBSV) filed an 8-K detailing director/officer changes and votes. Watch for governance shifts.
AI Summary
Pharma-Bio Serv, Inc. filed an 8-K on May 2, 2024, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits. The company, formerly known as Lawrence Consulting Group Inc., is incorporated in Delaware and headquartered in Dorado, Puerto Rico.
Why It Matters
This filing indicates significant changes in the company's leadership and governance structure, which could impact its strategic direction and operational management.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with votes by security holders, can signal potential shifts in strategy or internal dynamics that may affect the company's performance.
Key Players & Entities
- Pharma-Bio Serv, Inc. (company) — Registrant
- Lawrence Consulting Group Inc. (company) — Former company name
- May 2, 2024 (date) — Date of Report
FAQ
What specific changes were made regarding the departure and election of directors?
The filing indicates the departure of directors and the election of new directors, though specific names are not detailed in the provided text.
Were any new officers appointed as part of this filing?
Yes, the filing explicitly mentions the appointment of certain officers.
What is the significance of the 'Submission of Matters to a Vote of Security Holders' item?
This indicates that the company presented certain proposals or issues for shareholders to vote on during a meeting or via proxy.
What type of financial information is included with this 8-K?
The filing states that 'Financial Statements and Exhibits' are being submitted, suggesting updated financial data is part of the report.
When did Pharma-Bio Serv, Inc. change its name from Lawrence Consulting Group Inc.?
The date of the name change was September 23, 2004.
Filing Stats: 721 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-05-02 17:20:07
Filing Documents
- pbsv_8k.htm (8-K) — 33KB
- pbsv_ex101.htm (EX-10.1) — 6KB
- 0001654954-24-005476.txt ( ) — 149KB
- pbsv-20240502.xsd (EX-101.SCH) — 6KB
- pbsv-20240502_lab.xml (EX-101.LAB) — 12KB
- pbsv-20240502_cal.xml (EX-101.CAL) — 1KB
- pbsv-20240502_pre.xml (EX-101.PRE) — 8KB
- pbsv-20240502_def.xml (EX-101.DEF) — 2KB
- pbsv_8k_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. The following matters were voted upon at the Annual Meeting. Kirk Michel and Dov Perlysky were elected as Class II directors to serve for a term until the 2027 Annual Meeting of Stockholders or until his successor is duly elected and qualified. Kirk Michel and Dov Perlysky received the following votes: Nominee Votes For Votes Withheld Kirk Michel 12,647,540 3,857,021 Dov Perlysky 7,546,374 8,958,187 There were 1,714,854 broker non-votes on this proposal. The ratification of the selection of Crowe PR PSC as the Company's independent certified public accountants for the fiscal year ending October 31, 2024 received the following votes: Votes For Votes Against Abstain 14,364,694 1,500 3,853,221 There were no broker non-votes on this proposal. The approval of the Plan Amendment received the following votes: Votes For Votes Against Abstain 7,523,008 5,127,032 3,854,521 There were 1,714,854 broker non-votes on this proposal.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1+ Amendment to Pharma-Bio Serv, Inc. 2014 Long-Term Incentive Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) + Management Compensatory Plan 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHARMA-BIO SERV, INC. Date: May 2, 2024 By: /s/ Pedro J. Lasanta Pedro J. Lasanta Chief Financial Officer, Vice President Finance and Administration and Secretary 3